You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
貝達藥業(300558.SZ):前三季淨利預增145%至175%
格隆匯 10-14 22:51

格隆匯 10 月 14日丨貝達藥業(300558.SZ)披露2020年前三季度業績預告,2020年1月1日至2020年9月30日預計歸屬於上市公司股東的淨利潤4.86億元至5.46億元,比上年同期上升145%至175%。其中,第三季度業績預計歸屬於上市公司股東的淨利潤3.43億元至4.02億元,比上年同期上升208.10%至261.66%。

報告期內,公司預計歸屬於上市公司股東的淨利潤同比大幅上升,其中非經常性損益對淨利潤的影響金額預計為24,000.00萬元至25,000.00萬元,主要系報告期內公司出售浙江貝達醫藥科技有限公司股權的投資收益。

同時,公司營業收入保持良好的增長態勢。由於埃克替尼療效確切、肝毒性低、安全性高,循證醫學臨牀證據豐富,中國人羣數據全,在CSCO指南、衞健委診療規範及腦轉移人羣、21-L858RNSCLC患者中獲優先推薦,也是目前唯一繼續開展後續免費用藥項目的一代EGFR-TKI原研藥,具有明顯的差異化優勢。憑藉前述差異化優勢及多年的口碑積累,埃克替尼銷量繼續穩步增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account